Paul Estrem Net Worth & Insider Trades

Paul Estrem - Chief Financial Officer, Melinta Therapeutics, Inc

As of June 14, 2018

What is Paul Estrem's Net Worth?

The current estimated net worth of Melinta Therapeutics, Inc's Chief Financial Officer, Paul Estrem, is estimated to be about $50K . Paul Estrem owns about 10,000 units of Melinta Therapeutics, Inc common stock. Recently at Melinta Therapeutics, Inc, Paul Estrem has sold an estimated value of $0 worth.

What is Paul Estrem's Past Insider Trading?

Paul Estrem's largest purchase order was 10,000 units , worth over $50K on May 31, 2018. In total, Paul Estrem has made about 2 transactions recently at Melinta Therapeutics, Inc. Paul Estrem usually trades in May and June, with the busiest year in 2018.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Paul Estrem

Date Range: All Time
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...

InsideArbitrage

Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What is Paul Estrem's' Mailing Address?

  • Mailing address is 300 Tri-State International, Suite 272 Lincolnshire IL 60069 IL

What are Melinta Therapeutics, Inc's Past Insider Trades?

Melinta Therapeutics, Inc's most recent insider trade came on July 2, 2019 by John Johnson who sold 13,000 units worth $72.44K . In the last year, insiders at Melinta Therapeutics, Inc have sold an estimated value of $72.44K and bought an estimated value of $194.86M worth of shares. Insider trading is most common in June, with the busiest year in 2018. The most active traders at the company are John Johnson, Chief Executive Officer,  Kevin Ferro, Director,  and David Gill, Director .

MELINTA THERAPEUTICS, INC. /NEW/ Insider Trades

Date Range: All Time
Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
Loading...